List of bibliographic references
Number of relevant bibliographic references: 6.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Prostate cancer |
| 2 | Aged |
| 2 | Bone Neoplasms (secondary) |
| 2 | Bone metastasis |
| 2 | Cancerology |
| 2 | Chemotherapy |
| 2 | Denosumab |
| 2 | Double-Blind Method |
| 2 | Humans |
| 2 | Male |
| 2 | Medicine |
| 2 | Survival |
| 2 | Treatment |
| 1 | Abiraterone |
| 1 | Adult |
| 1 | Advanced stage |
| 1 | Aged, 80 and over |
| 1 | Androgen Antagonists (therapeutic use) |
| 1 | Androstenes (therapeutic use) |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 1 | Antineoplastic Agents (administration & dosage) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Agents, Hormonal (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols |
| 1 | Antineoplastic agent |
| 1 | Antiresorptive agent |
| 1 | Biomarkers, Tumor (blood) |
| 1 | Bone Neoplasms (diagnosis) |
| 1 | Bone Neoplasms (drug therapy) |
| 1 | Bone Neoplasms (mortality) |
| 1 | Castration |
| 1 | Castration (methods) |
| 1 | Clinical trial |
| 1 | Disease Progression |
| 1 | Disease-Free Survival |
| 1 | Doubling time |
| 1 | Drug Administration Schedule |
| 1 | Follow-Up Studies |
| 1 | Human |
| 1 | Immunomodulator |
| 1 | Injections, Subcutaneous |
| 1 | Metastasis |
| 1 | Metastatic |
| 1 | Neoplasm Staging |
| 1 | Odds Ratio |
| 1 | Phase III trial |
| 1 | Prednisone (therapeutic use) |
| 1 | Prevention |
| 1 | Prognosis |
| 1 | Prostate specific antigen |
| 1 | Prostate-Specific Antigen (blood) |
| 1 | Prostatic Neoplasms (blood) |
| 1 | Prostatic Neoplasms (drug therapy) |
| 1 | Prostatic Neoplasms (metabolism) |
| 1 | Prostatic Neoplasms (pathology) |
| 1 | Prostatic Neoplasms, Castration-Resistant (drug therapy) |
| 1 | Prostatic Neoplasms, Castration-Resistant (mortality) |
| 1 | Prostatic Neoplasms, Castration-Resistant (pathology) |
| 1 | RANK Ligand (antagonists & inhibitors) |
| 1 | Resistance |
| 1 | Skeleton |
| 1 | Survival Rate |
| 1 | Time Factors |
| 1 | Treatment Outcome |
| 1 | Tumoral marker |
| 1 | Zoledronic acid |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Fred Saad"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Fred Saad" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Fred Saad
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
